SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
MWN-AI** Summary
SciSparc Ltd. (Nasdaq: SPRC) has announced a significant advancement through its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX). The collaboration with Clearmind Medicine Inc. has resulted in a patent application being filed for a novel therapy aimed at treating major depressive disorder (MDD). The innovative treatment combines Clearmind’s proprietary compound, 5-methoxy-2-aminoindane (MEAI), with Palmitoylethanolamide (PEA), provided by NeuroThera. This synergy is positioned as a non-hallucinogenic neuroplastogen, potentially offering a safer and more cost-effective alternative to traditional antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs).
The World Health Organization has highlighted MDD’s prominence as a global concern, affecting over 332 million individuals worldwide. The collaborative effort reflects SciSparc's strategic focus on developing cannabinoid-based pharmaceuticals, which includes its current drug development programs targeting conditions like Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder.
SciSparc emphasizes the forward-looking potential of this patented therapy, citing its ability to improve accessibility and safety in the treatment of depression. However, they caution that these statements are subject to various risks and uncertainties, and actual outcomes may diverge from expectations. The company advises investors to review its risk factors as outlined in their regulatory filings.
This collaboration marks a noteworthy step in SciSparc's commitment to addressing significant unmet medical needs in mental health, with the promise of introducing innovative solutions to longstanding challenges in the pharmaceutical landscape. For further details or inquiries, stakeholders are encouraged to reach out to SciSparc’s investor relations.
MWN-AI** Analysis
SciSparc Ltd. (Nasdaq: SPRC) is at a pivotal stage in its development following its collaboration with NeuroThera Labs and Clearmind Medicine, resulting in a significant patent application for a novel therapy targeting major depressive disorder (MDD). This innovative combination of Clearmind's 5-methoxy-2-aminoindane (MEAI) and NeuroThera's Palmitoylethanolamide (PEA) presents a promising avenue in a market desperate for effective, non-hallucinogenic alternatives to traditional antidepressants, particularly given the staggering worldwide prevalence of depression.
Investors should closely monitor SciSparc’s progress as this therapy moves through clinical testing and regulatory scrutiny. The patent filing is a strong indicator of the potential efficacy and market demand for this treatment, which could offer a safer and more affordable option for millions suffering from MDD. If successfully commercialized, it may not only reshape the existing antidepressant market dominated by SSRIs but also pave the way for further innovations in the CNS disorder space.
Furthermore, with SciSparc holding a 75% stake in NeuroThera, it stands to benefit substantially from any advances in this collaboration. The potential for licensing agreements or partnerships with larger pharmaceutical companies could provide significant revenue streams, enhancing investor sentiment and potentially leading to an uplift in stock valuation.
However, prospective investors should also heed the risks outlined in SciSparc’s forward-looking statements—such as the unpredictability of clinical trial outcomes, regulatory challenges, and market competition. It is crucial to remain cognizant of these factors, alongside extensive market research and analysis, when considering an investment in SciSparc. A balanced approach that weighs potential rewards against inherent risks will be essential for navigating this emerging sector of mental health therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).
This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.
The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and other conventional options.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages from the therapy under the patent, and that therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ**
How does SciSparc Ltd. SPRC plan to leverage its controlling interest in NeuroThera Labs to further develop the innovative MEAI-PEA combination therapy for major depressive disorder?
What are the key milestones expected by SciSparc Ltd. SPRC in the clinical development of therapies for other CNS disorders such as Tourette syndrome and Alzheimer's disease?
Can SciSparc Ltd. SPRC provide insights into the competitive landscape for neuroplastogen treatments for MDD and how it differentiates its MEAI-PEA therapy from existing options?
What risks and uncertainties does SciSparc Ltd. SPRC foresee in the commercialization of its novel therapeutic approaches, particularly regarding the newly patented MEAI-PEA therapy for depression?
**MWN-AI FAQ is based on asking OpenAI questions about SciSparc Ltd. (NASDAQ: SPRC).
NASDAQ: SPRC
SPRC Trading
25.97% G/L:
$11.69 Last:
8,514,167 Volume:
$13.55 Open:
